Loading...
Multiple agents that target various facets of biochemical damage in the brain following stroke have been tested as neuroprotectants without success in the last few decades. Most of these agents have targeted a single mechanism, such as the NMDA receptor or free radicals (acting as a scavenger). Whether an agent with more than one action will improve outcomes of stroke is unknown.
These researchers conducted an industry-funded, randomized, controlled trial at 33 centers in China to evaluate sublingual edaravone and dexborneol, a combination not currently approved in the U.S. Edaravone acts as an oxygen radical scavenger, whereas dexborneol is reported to have anti-inflammatory properties. Patients aged 18 to 80 years were enrolled with a qual…